Jun 08, 2023 / 08:30PM GMT
Srishti Kotiyal - Jefferies - Analyst
Good afternoon, and welcome to the Jefferies Global Healthcare Conference. My name is Srishti Kotiyal, and I'm with the Jefferies Investment Banking team. It is my great pleasure to introduce Remi Barbier, President and CEO of Cassava Sciences.
Remi Barbier - Cassava Sciences, Inc. - President & CEO
Thank you, and thank you, Jefferies, for inviting us to the Global Health Care Conference. So, my name is Remi Barbier, I'm the Founder, and President, and CEO of Cassava Sciences. The theme, the thing that we will talk about today is Alzheimer's disease and drug development in Alzheimer's disease. Before we get into the presentation, we are a public company, so yes, we have forward-looking statements and a Safe Harbor statement. Please read it carefully. Drug development is definitely a high-risk, high-reward activity.
So a brief introduction to Cassava Sciences. We are developing a novel drug treatment for patients with AD or Alzheimer's disease. Importantly, our science is based on stabilizing an altered form of a
Cassava Sciences Inc at Jefferies Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot